Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.154.50 CHF
Change Today -0.80 / -0.52%
Volume 1.4K
COPN On Other Exchanges
SIX Swiss Ex
As of 6:29 AM 10/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

37C, avenue John F. Kennedy

Luxembourg, 1855


Phone: 352 2784 8749


Cosmo Pharmaceuticals S.p.A. operates as a specialty pharmaceutical company primarily in Italy. The company develops, licenses, and commercializes proprietary pharmaceutical products, primarily for the treatment of inflammatory bowel diseases, colon infections, and other colon diseases, as well as topically treated skin disorders; and manufactures pharmaceutical products for third parties and provides related services. Its products comprise Lialda, Mezavant, and Mesavancol proprietary formulations for mild to moderate ulcerative colitis; Uceris and Cortiment products for mild to moderate ulcerative colitis; and Zacol NMX, a nutraceutical product for intestinal disorders. The company also develops various products, including CB-17-01 Methylene Blue MMX, a vital dye which stains the living cells that is in Phase III clinical trials for colon cancer; SIC 8000, a submucosal injectable composition developed to reduce the risk of perforation when resecting flat polyps and to allow the resection of large polyps in one piece; Rifamycin SV MMX, a semisynthetic, orally poorly absorbable antibiotic for the treatment of bacterial infections of the colon, which has completed phase III clinical trials in traveler’s diarrhea; CB-03-01, a steroidal anti-androgen drug, cortexolone 17a-proprionate (CB-03-01) 1% cream, targeted at acne, alopecia, hirsutism and possibly seborrhea that has Phase II clinical trials for acne; CB-06-02, a tellurium-based compound for the topical treatment of HPV and genital warts that is in Phase II trial; and CB-06-01, a topical antibiotic for the treatment of acne, which in Phase II trial. The company is headquartered in Luxembourg.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COPN:SW SFr.154.50 CHF -0.80

COPN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $59.77 USD -0.71
Depomed Inc $19.91 USD +0.09
Durect Corp $2.05 USD -0.02
Supernus Pharmaceuticals Inc $15.01 USD -0.32
Veloxis Pharmaceuticals A/S kr1.25 DKK +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation COPN Industry Range
Price/Earnings 8.8x
Price/Sales 34.1x
Price/Book 5.1x
Price/Cash Flow 8.7x
TEV/Sales 33.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COSMO PHARMACEUTICALS SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at